Abstract:The protein arginine methyltransferase (PRMT) family of enzymes comprises nine family members in mammals. They catalyze arginine methylation, either monomethylation or symmetric/asymmetric dimethylation of histone and non-histone proteins. PRMT methylation of its substrate proteins modulates cellular processes such as signal transduction, transcription, and mRNA splicing. Recent studies have linked overexpression of PRMT5, a member of the PRMT superfamily, to oncogenesis, making it a potential target for cancer therapy. In this study, we developed a highly sensitive (Z' score = 0.7) robotic high throughput screening (HTS) platform to discover small molecule inhibitors of PRMT5 by adapting the AlphaLISA™ technology. Using biotinylated histone H4 as a substrate, and S-adenosyl-l-methionine as a methyl donor, PRMT5 symmetrically dimethylated H4 at arginine (R) 3. Highly specific acceptor beads for symmetrically dimethylated H4R3 and streptavidin-coated donor beads bound the substrate, emitting a signal that is proportional to the methyltransferase activity. Using this powerful approach, we identified specific PRMT5 inhibitors P1608K04 and P1618J22, and further validated their efficacy and specificity for inhibiting PRMT5. Importantly, these two compounds exhibited much more potent efficacy than the commercial PRMT5 inhibitor EPZ015666 in both pancreatic and colorectal cancer cells. Overall, our work highlights a novel, powerful, and sensitive approach to identify specific PRMT5 inhibitors. The general principle of this HTS screening method can not only be applied to PRMT5 and the PRMT superfamily, but may also be extended to other epigenetic targets. This approach allows us to identify compounds that inhibit the activity of their respective targets, and screening hits like P1608K04 and P1618J22 may serve as the basis for novel drug development to treat cancer and/or other diseases.

Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1

Molecular Mechanism underlying PRMT1 Dimerization for SAM Binding and Methylase Activity

Substrate Specificity, Processivity, and Kinetic Mechanism of Protein Arginine Methyltransferase 5

Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation

Small Molecule Inhibitors of Protein Arginine Methyltransferases

Protein arginine methylation: from enigmatic functions to therapeutic targeting

Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-Yl)anilines Core Identified by Virtual Screening and Biological Evaluation.

Chemical probes and methods for the study of protein arginine methylation

Design and synthesis of novel PRMT1 inhibitors and investigation of their binding preferences using molecular modelling

Structure, Function, and Activity of Small Molecule and Peptide Inhibitors of Protein Arginine Methyltransferase 1

Oligomerization of protein arginine methyltransferase 1 and its effect on methyltransferase activity and substrate specificity

The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors

Inhibitory Study of Protein Arginine Methyltransferase 1 Using a Fluorescent Approach.

Structural Insights Into Protein Arginine Symmetric Dimethylation By Prmt5

Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1)

The Role of PRMT1 in Cellular Regulation and Disease: Insights into Biochemical Functions and Emerging Inhibitors for Cancer Therapy

Overview of PRMT1 modulators: Inhibitors and degraders

A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases

Independent transcriptomic and proteomic regulation by type I and II protein arginine methyltransferases

Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)

Development of an AlphaLISA High Throughput Technique to Screen for Small Molecule Inhibitors Targeting Protein Arginine Methyltransferases